Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIDE: Daratumumab + TMZ/RT in Glioblastoma
NCT04922723Phase 2Active, not recruiting
- Sponsor
- West Virginia University
- Start
- Oct 2022
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in glioblastoma (GBM), sponsored by West Virginia University. Primary endpoints: Dose Limiting Toxicity at 6 weeks and Overall Survival at 12 months. Started Oct 2022; status: active, not recruiting.
02
Drugs
daratumumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04922723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04922723.